Fabrizio Nannipieri Selected Research

ABIO 0801

1/2009

Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Fabrizio Nannipieri Research Topics

Disease

3	COVID-19 12/2023 - 01/2023
2	Post-Acute COVID-19 Syndrome 12/2023 - 01/2023
2	Vitamin D Deficiency 12/2023 - 01/2023
2	Complex Regional Pain Syndromes 01/2022 - 01/2021
2	Pain (Aches) 01/2022 - 01/2021
1	Sarcopenia 10/2022
1	Chronic Pain 01/2022
1	Celiac Disease (Celiac Sprue) 01/2022
1	Osteoporosis 06/2021
1	Edema (Dropsy) 01/2021
1	Hyperalgesia 01/2021
1	Anxiety Disorders (Anxiety Disorder) 01/2009

Drug/Important Bio-Agent (IBA)

4	Vitamin D FDA LinkGeneric 12/2023 - 01/2022
3	hydroxide ionIBA 12/2023 - 01/2023
2	6- amino- 1- hydroxyhexane- 1,1- diphosphonateIBA 01/2022 - 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 12/2023
1	BNT162 VaccineIBA 12/2023
1	VaccinesIBA 12/2023
1	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 10/2022
1	Leucine (L-Leucine)FDA Link 10/2022
1	Cholecalciferol (Vitamin D3)FDA Link 01/2022
1	Diphosphonates (Bisphosphonates)IBA 01/2022
1	ABIO 0801IBA 01/2009

Therapy/Procedure

1	Transplantation 06/2021